- In March 2023, Celtaxsys concluded Phase 2 of a pragmatic, multi-arm, adaptive, blinded, randomized placebo-controlled platform trial for Acebilustat (CTX-4430). The trial aimed to assess various investigational therapeutics' efficacy in reducing time to disease resolution or viral load cessation in COVID-19 outpatients, compared to standard supportive care. This approach offers insights into potential treatments for managing COVID-19 outside of hospital settings
